Immuron Ltd Stock Price, News & Analysis

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has signed a strategic investment agreement with Ateria Health, investing approximately £1.5m (A$2.6m) for a 17.5% stake. This agreement includes an option for further investment of £1.47m by July 31, 2023. Ateria Health specializes in gut health supplements, with its product JUVIA™ targeting irritable bowel syndrome (IBS). The partnership aims to enhance distribution channels for both companies in the UK, Australia, and North America.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced significant developments in its clinical research. A Master Service Agreement with US-based Pharmaron has been executed to initiate a Phase II clinical trial evaluating the single-dose regimen of Travelan® for protecting against travelers’ diarrhea caused by ETEC. This trial will enroll 60 healthy volunteers in the USA, with results expected in 2H 2023. The company also plans to submit an Investigational New Drug (IND) application to the FDA by the end of 2022, funded partly by a AU$6.2 million award from the US Department of Defense.

MELBOURNE, Australia, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Immuron Limited (ASX: IMC; NASDAQ: IMRN) invites investors to a live webcast hosted by CEO Steven Lydeamore on September 7, 2022, at 9:00 AM AEST. The event aims to discuss the company's proprietary technology for gut-mediated disease treatment. Interested participants can register in advance for the webinar. This press release is authorized by the directors of Immuron Limited, which is focused on developing orally delivered polyclonal antibodies from bovine colostrum.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced a strategic shift on August 19, 2022, deprioritizing its SARS-CoV-2 research to focus on advanced therapeutic drug candidates. The company is entering FY23 with a new CEO assessing its product portfolio and growth strategies. Immuron's previous research indicated the potential antiviral activity of its drug candidate IMM-124E against SARS-CoV-2, but the mechanism of action remains unclear. The evolving virus and treatment landscape pose challenges for clinical trials.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) announced that the US Naval Medical Research Center (NMRC) received feedback from the US FDA regarding its Investigational New Drug (IND) application for a new oral therapeutic targeting Campylobacter and ETEC. The FDA identified insufficient information under 21 CFR 312.23 for assessing risks in proposed clinical studies, placing the IND on Clinical Hold. NMRC plans to address these comments and will seek a Type A meeting with the FDA within 30 days to discuss amendments and requirements for moving forward.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) reported significant sales growth for FY22. North American sales of Travelan® surged by 494%, reaching AU $0.6M, while global sales rose 431% to AU $0.9M. Sales in the US were particularly strong, increasing from AU $4K in FY21 to AU $0.6M in FY22, driven by sales through Passport Health Travel Clinics and Amazon. In Australia, sales of Travelan® and Protectyn® also grew, totaling AU $0.3M in FY22. Immuron aims to expand its product portfolio while benefiting from the recovering travel sector.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced receiving a notification of the Intent to Grant a European Patent for treatments related to Clostridioides difficile associated disease. This patent, numbered 14784945.9, focuses on methods and compositions for both treatment and prevention of the infection. Alongside patents in Australia, New Zealand, and the U.S., this grant strengthens Immuron's intellectual property in an area with significant health and economic impact, as Clostridioides difficile infections can result in severe complications and considerable healthcare costs globally.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) has announced that the US Naval Medical Research Center (NMRC) submitted an IND application to the FDA for a new oral therapeutic targeting Campylobacter and ETEC. This initiates two human phase II clinical trials, with one trial aimed at preventing infectious diarrhea caused by ETEC, set to start in July 2022, and another focused on moderate to severe campylobacteriosis. The trials will recruit 60 volunteers, testing the product's safety and efficacy against these pathogens.

Immuron Limited (ASX: IMC; NASDAQ: IMRN) provides an update on its clinical trial evaluating the efficacy of Travelan^® against two non-antibiotic products for Travelers’ Diarrhea (TD). Manufacture of investigational medical products is complete, and initial shipments have been dispatched. The clinical protocol has been amended to extend the treatment period from 13 to 22 days due to COVID-19 quarantine requirements. Planned enrollment of 1,336 participants is expected to begin in June 2022, with completion anticipated within 18 months.